177 related articles for article (PubMed ID: 34064473)
1. Prognostic Significance of BIRC5/Survivin in Breast Cancer: Results from Three Independent Cohorts.
Oparina N; Erlandsson MC; Fäldt Beding A; Parris T; Helou K; Karlsson P; Einbeigi Z; Bokarewa MI
Cancers (Basel); 2021 May; 13(9):. PubMed ID: 34064473
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Role of Survivin and Macrophage Infiltration Quantified on Protein and mRNA Level in Molecular Subtypes Determined by RT-qPCR of
Ecke TH; Kiani A; Schlomm T; Friedersdorff F; Rabien A; Jung K; Kilic E; Boström P; Tervahartiala M; Taimen P; Gleichenhagen J; Johnen G; Brüning T; Koch S; Roggisch J; Wirtz RM
Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33050010
[TBL] [Abstract][Full Text] [Related]
3. Identification of prognostic significance of BIRC5 in breast cancer using integrative bioinformatics analysis.
Dai JB; Zhu B; Lin WJ; Gao HY; Dai H; Zheng L; Shi WH; Chen WX
Biosci Rep; 2020 Feb; 40(2):. PubMed ID: 32043523
[TBL] [Abstract][Full Text] [Related]
4. Polymorphisms in Survivin (
Sušac I; Ozretić P; Gregorić M; Levačić Cvok M; Sabol M; Levanat S; Trnski D; Eljuga D; Seiwerth S; Aralica G; Stanec M; Musani V
J Oncol; 2019; 2019():3483192. PubMed ID: 31467536
[TBL] [Abstract][Full Text] [Related]
5. Significance of Nuclear Factor-Kappa B (NF-κB) and Survivin in Breast Cancer and Their Association with Radiosensitivity and Prognosis.
Cao Q; Ai XQ; Mushajiang M
Breast Cancer (Dove Med Press); 2023; 15():175-188. PubMed ID: 36923396
[TBL] [Abstract][Full Text] [Related]
6. The prognostic significance of BMI1 expression in invasive breast cancer is dependent on its molecular subtypes.
Althobiti M; Muftah AA; Aleskandarany MA; Joseph C; Toss MS; Green A; Rakha E
Breast Cancer Res Treat; 2020 Aug; 182(3):581-589. PubMed ID: 32524353
[TBL] [Abstract][Full Text] [Related]
7. BIRC5 expression by race, age and clinical factors in breast cancer patients.
Hamilton AM; Walens A; Van Alsten SC; Olsson LT; Nsonwu-Farley J; Gao X; Kirk EL; Perou CM; Carey LA; Troester MA; Abdou Y
Breast Cancer Res; 2024 Mar; 26(1):50. PubMed ID: 38515208
[TBL] [Abstract][Full Text] [Related]
8. Mediator complex (MED) 7: a biomarker associated with good prognosis in invasive breast cancer, especially ER+ luminal subtypes.
Joseph C; Macnamara O; Craze M; Russell R; Provenzano E; Nolan CC; Diez-Rodriguez M; Sonbul SN; Aleskandarany MA; Green AR; Rakha EA; Ellis IO; Mukherjee A
Br J Cancer; 2018 Apr; 118(8):1142-1151. PubMed ID: 29588513
[TBL] [Abstract][Full Text] [Related]
9. Pan-cancer analysis identifies BIRC5 as a prognostic biomarker.
Fäldt Beding A; Larsson P; Helou K; Einbeigi Z; Parris TZ
BMC Cancer; 2022 Mar; 22(1):322. PubMed ID: 35331169
[TBL] [Abstract][Full Text] [Related]
10. The solute carrier SLC7A8 is a marker of favourable prognosis in ER-positive low proliferative invasive breast cancer.
El Ansari R; Alfarsi L; Craze ML; Masisi BK; Ellis IO; Rakha EA; Green AR
Breast Cancer Res Treat; 2020 May; 181(1):1-12. PubMed ID: 32200487
[TBL] [Abstract][Full Text] [Related]
11. [Expression of the antiapoptotic protein survinin and its gene in primary breast carcinoma].
Shlyakhtunov YA; Klopova VA
Arkh Patol; 2019; 81(2):18-23. PubMed ID: 31006775
[TBL] [Abstract][Full Text] [Related]
12. Myxovirus resistance 1 (MX1) is an independent predictor of poor outcome in invasive breast cancer.
Aljohani AI; Joseph C; Kurozumi S; Mohammed OJ; Miligy IM; Green AR; Rakha EA
Breast Cancer Res Treat; 2020 Jun; 181(3):541-551. PubMed ID: 32350677
[TBL] [Abstract][Full Text] [Related]
13. The prognostic significance of STAT3 in invasive breast cancer: analysis of protein and mRNA expressions in large cohorts.
Aleskandarany MA; Agarwal D; Negm OH; Ball G; Elmouna A; Ashankyty I; Nuglozeh E; Fazaludeen MF; Diez-Rodriguez M; Nolan CC; Tighe PJ; Green AR; Ellis IO; Rakha EA
Breast Cancer Res Treat; 2016 Feb; 156(1):9-20. PubMed ID: 26907764
[TBL] [Abstract][Full Text] [Related]
14. Clinical and biological roles of Kelch-like family member 7 in breast cancer: a marker of poor prognosis.
Kurozumi S; Joseph C; Sonbul S; Gorringe KL; Pigera M; Aleskandarany MA; Diez-Rodriguez M; Nolan CC; Fujii T; Shirabe K; Kuwano H; Storr S; Martin SG; Ellis IO; Green AR; Rakha EA
Breast Cancer Res Treat; 2018 Aug; 170(3):525-533. PubMed ID: 29633055
[TBL] [Abstract][Full Text] [Related]
15. Kinesin family member-18A (KIF18A) is a predictive biomarker of poor benefit from endocrine therapy in early ER+ breast cancer.
Alfarsi LH; Elansari R; Toss MS; Diez-Rodriguez M; Nolan CC; Ellis IO; Rakha EA; Green AR
Breast Cancer Res Treat; 2019 Jan; 173(1):93-102. PubMed ID: 30306428
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of interferon regulating factor 4 (IRF4) in node-negative breast cancer.
Heimes AS; Madjar K; Edlund K; Battista MJ; Almstedt K; Gebhard S; Foersch S; Rahnenführer J; Brenner W; Hasenburg A; Hengstler JG; Schmidt M
J Cancer Res Clin Oncol; 2017 Jul; 143(7):1123-1131. PubMed ID: 28251349
[TBL] [Abstract][Full Text] [Related]
17. Dysregulation of miR-195-5p/-218-5p/BIRC5 axis predicts a poor prognosis in patients with gastric cancer.
Zou J; Liao X; Zhang J; Wang L
J Biol Regul Homeost Agents; 2019; 33(5):1377-1385. PubMed ID: 31663299
[TBL] [Abstract][Full Text] [Related]
18. miR-138-5p contributes to cell proliferation and invasion by targeting Survivin in bladder cancer cells.
Yang R; Liu M; Liang H; Guo S; Guo X; Yuan M; Lian H; Yan X; Zhang S; Chen X; Fang F; Guo H; Zhang C
Mol Cancer; 2016 Dec; 15(1):82. PubMed ID: 27978829
[TBL] [Abstract][Full Text] [Related]
19. BIRC5 (survivin): a pejorative prognostic marker in stage II/III breast cancer with no response to neoadjuvant chemotherapy.
Hamy AS; Bieche I; Lehmann-Che J; Scott V; Bertheau P; Guinebretière JM; Matthieu MC; Sigal-Zafrani B; Tembo O; Marty M; Asselain B; Spyratos F; de Cremoux P
Breast Cancer Res Treat; 2016 Oct; 159(3):499-511. PubMed ID: 27592112
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of KN motif and ankyrin repeat domains 1 (KANK1) in invasive breast cancer.
Kariri YA; Joseph C; Kurozumi S; Toss MS; Alsaleem M; Raafat S; Mongan NP; Aleskandarany MA; Green AR; Rakha EA
Breast Cancer Res Treat; 2020 Jan; 179(2):349-357. PubMed ID: 31679074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
